{"schema_version":"secwatch.filing_event.v1","accession":"0001789769-26-000004","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2026-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.189687+00:00","generated_at":"2026-05-16T11:32:59.647481+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Instil Bio subsidiary terminates license deal with ImmuneOnco for AXN-2510 and AXN-27M","bullets":["Axion Bio (Instil Bio subsidiary) terminated License and Collaboration Agreement with ImmuneOnco effective Jan 5, 2026.","Agreement, dated Aug 1, 2024, granted Axion ex-China rights to AXN-2510 and AXN-27M.","No details provided on termination reason or financial impact on Instil Bio."],"urls":{"canonical":"https://secwatch.observer/filing/0001789769-26-000004","json":"https://secwatch.observer/filing/0001789769-26-000004.json","markdown":"https://secwatch.observer/filing/0001789769-26-000004.md","text":"https://secwatch.observer/filing/0001789769-26-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000178976926000004/0001789769-26-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000178976926000004/til-20260105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:32:59.647481+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4fc1981f297dc91792462dad1c726b5f8c582473","claim":"Instil Bio, Inc. terminated License and Collaboration Agreement with ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (effective 2026-01-05).","evidence_excerpt":"Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil Bio, Inc., and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (“ImmuneOnco”) entered into an agreement terminating, effective January 5, 2026, the License and Collaboration Agreement dated August 1, 2024 between ImmuneOnco and Axion","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789769/000178976926000004/0001789769-26-000004-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc."},{"label":"Effective","value":"2026-01-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}